ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

INDV Indivior Plc

738.00
-20.50 (-2.70%)
Last Updated: 11:12:57
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BN4HT335 ORD USD0.50
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -20.50 -2.70% 738.00 738.00 740.00 751.50 721.50 751.50 37,829 11:12:57
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 1.19B 2M 0.0160 451.88 947.39M

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

07/11/2024 7:24pm

PR Newswire (US)


Indivior (LSE:INDV)
Historical Stock Chart


From Sep 2024 to Mar 2025

Click Here for more Indivior Charts.

RICHMOND, Va., Nov. 7, 2024 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a letter from Oaktree Capital Management LP ("Oaktree") to the Board of Indivior.

Indivior (PRNewsfoto/Indivior)

The Board has engaged actively with Oaktree in recent weeks on these topics, and remains open-minded about all proposals to enhance value creation. The Board is focused on acting in the best interests of all shareholders as we continue to execute on our strategy.

Indivior looks forward to further engagement with Oaktree and other shareholders. 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD). Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-responds-to-publication-of-a-letter-by-oaktree-capital-management-to-the-board-of-indivior-302299220.html

SOURCE Indivior PLC

Copyright 2024 PR Newswire

1 Year Indivior Chart

1 Year Indivior Chart

1 Month Indivior Chart

1 Month Indivior Chart